For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Impact of Multiphase 68Ga-DOTATOC-PET/CT on Therapy Management in Patients with Neuroendocrine TumorsRuf J.a · Heuck F.c · Schiefer J.a · Denecke T.d · Elgeti F.d · Pascher A.e · Pavel M.c · Stelter L.d, f · Kropf S.b · Wiedenmann B.c · Amthauer H.a, d
aKlinik für Radiologie und Nuklearmedizin, and bInstitut für Biometrie und Medizinische Informatik, Universitätsklinikum Magdeburg A.ö.R, Magdeburg, cMedizinische Klinik m. S. Hepatologie und Gastroenterologie, Charité Centrum 13 für Innere Medizin mit Kardiologie, Gastroenterologie, und Nephrologie, dKlinik Strahlenheilkunde, Charité Centrum 6 für diagnostische und interventionelle Radiologie und Nuklearmedizin, and eKlinik für Allgemein-, Viszeral- und Transplantationschirurgie, Charité Centrum 8 für Chirurgische Medizin, Campus Virchow-Klinikum, Charité-Universitätsmedizin, Berlin, Germany; fNuclear Medicine Research Laboratory, Memorial Sloan-Kettering Cancer Center, New York City, N.Y., USA
Aim: Retrospective evaluation of the impact of integrated positron emission tomography/computed tomography (PET/CT) using 68Ga-DOTA(0)-Phe(1)-Tyr(3)-octreotide (68Ga-DOTATOC) on the therapeutic management of patients with neuroendocrine tumors (NET). Methods: The 68Ga-DOTATOC-PET/CT data of 66 patients (31 male, 35 female; age: 29–79, mean age: 56 years) with known or suspected NET were included. Imaging data (PET and triple-phase contrast-enhanced CT) were evaluated in consensus by two readers for the visualization of NET manifestations. Combined PET/CT, clinical and imaging follow-up as well as histopathology (if available) served as the reference standard. In order to assess the impact of the respective submodalities on the therapeutic strategy chosen, the results were compared to the treatment decision made by the interdisciplinary NET tumor board of our institution. Results: Two of the initial 66 patients included did not suffer from NET according to further immunohistopathological examination. In 50 of the remaining 64 (78%) NET patients, a total of 181 NET manifestations were detected by PET/CT. 59/181 (32.6%) were detected by one submodality only (CT 17.1%, PET 15.5%, p for comparison of both = 0.459). Combined PET/CT reading had an impact on the therapeutic management in 24 of 64 (38%) NET patients: primary resection (n = 5), curative lymph node resection (n = 1), initiation/switch of chemotherapy (CTx) due to progressive disease (n = 10), no surgery due to systemic disease (n = 2), radiopeptide receptor therapy instead of CTx (n = 1), additional bisphosphonate therapy (n = 4), and hepatic brachytherapy (n = 1). In 12 of 24 (50%) of these patients, relevant findings were detected by a single submodality only: CT (n = 5), PET (n = 7); p for comparison = 0.774). Conclusion:68Ga-DOTATOC-PET/CT influences therapeutic management in about one third of patients examined. CT and PET are comparably sensitive, deliver complementary information and equally contribute to therapeutic decision-making. Thus, despite the merits of the PET modality, the CT component must not be neglected and an optimized multiphase CT protocol is recommended.
© 2009 S. Karger AG, Basel